Joseph M. Luettgen
Bristol-Myers Squibb (United States)(US)
Publications by Year
Research Areas
Blood Coagulation and Thrombosis Mechanisms, Coagulation, Bradykinin, Polyphosphates, and Angioedema, Atrial Fibrillation Management and Outcomes, Vitamin K Research Studies, Hemophilia Treatment and Research
Most-Cited Works
- → Discovery of 1-(4-Methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro- 1H-pyrazolo[3,4-c]pyridine-3-carboxamide (Apixaban, BMS-562247), a Highly Potent, Selective, Efficacious, and Orally Bioavailable Inhibitor of Blood Coagulation Factor Xa(2007)391 cited
- → Apixaban, an oral, direct and highly selective factor Xa inhibitor: in vitro, antithrombotic and antihemostatic studies(2008)299 cited
- → Discovery of 1-(3‘-Aminobenzisoxazol-5‘-yl)-3-trifluoromethyl-N-[2-fluoro-4- [(2‘-dimethylaminomethyl)imidazol-1-yl]phenyl]-1H-pyrazole-5-carboxyamide Hydrochloride (Razaxaban), a Highly Potent, Selective, and Orally Bioavailable Factor Xa Inhibitor(2004)188 cited
- → Discovery of 1-[3-(Aminomethyl)phenyl]-N-[3-fluoro-2‘-(methylsulfonyl)- [1,1‘-biphenyl]-4-yl]-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide (DPC423), a Highly Potent, Selective, and Orally Bioavailable Inhibitor of Blood Coagulation Factor Xa(2001)172 cited
- → Discovery of Milvexian, a High-Affinity, Orally Bioavailable Inhibitor of Factor XIa in Clinical Studies for Antithrombotic Therapy(2021)97 cited
- → Preclinical pharmacokinetics and pharmacodynamics of apixaban, a potent and selective factor Xa inhibitor(2011)97 cited
- → Structure-Based Design of Novel Guanidine/Benzamidine Mimics: Potent and Orally Bioavailable Factor Xa Inhibitors as Novel Anticoagulants(2003)96 cited
- → Inhibition of Factor XIa as a New Approach to Anticoagulation(2010)95 cited
- → Apixaban, an oral direct factor Xa inhibitor, inhibits human clot-bound factor Xa activity in vitro(2009)91 cited
- → First‐in‐human study of milvexian, an oral, direct, small molecule factor XIa inhibitor(2021)87 cited